Emvision Medical Devices Ltd. · ASX:EMV
Emvision Medical Devices — Ord Minnett Biotech and Medtech Conference 2024
17 slides from Emvision Medical Devices's conference presentation, Nov 28, 2024
Slide 1: Ord Minnett Biotech and Medtech Conference November 2024
emvision.com.au For personal use only ORD MINNETT BIOTECH AND MEDTECH CONFERENCE NOVEMBER 2024 ASX:EMV First Responder Bedside Scanner Pre-hospital scanner
Slide 2: Disclaimer
DISCLAIMER This presentation has been prepared by EMVision Medical Devices Limited (“EMVision” or “the Company”). This presentation is not a financial product or For personal use only investment advice or recommendation, offer or invitation by any person or to any person to sell or purchase securiti
Slide 3: Company Overview
COMPANY OVERVIEW EMVision (ASX:EMV) is a medical device company developing and commercialising world-first portable brain scanner products to address significant unmet clinical needs For personal use only ➢ Founded in 2017 to advance and commercialise a decade of groundbreaking research out of the U
Slide 4: Meet the Team
MEET THE TEAM Significant medical device development and global commercialisation expertise across the group Executive Leadership Team Board of Directors For personal use only Scott Kirkland As former CEO of Queensland Diagnostic Imaging, Sales and marketing executive, former Head of John Keep CEO,
Slide 5: Our vision is to reduce the global burden of stroke and other time sensitive medical emergencies
OUR VISION IS TO REDUCE THE GLOBAL BURDEN OF STROKE AND OTHER TIME SENSITIVE MEDICAL EMERGENCIES First indication Second indication For personal use only Stroke Traumatic brain injury (TBI) Types of Stroke • 1 in 4 adults will suffer from a stroke in their • 50 to 60 million people worldwide will li
Slide 6: CT scanners are vital in stroke care, but not readily available at the point-of-care
CT SCANNERS ARE VITAL IN STROKE CARE, BUT ARE NOT READILY AVAILABLE AT THE POINT-OF-CARE CT scanners cannot be widely deployed at the bedside, or in remote locations, or in every ambulance. EMVision’s products can address this unmet need. For personal use only Mobile Stroke Units (MSUs) are custom-b
Slide 7: Accessible neurodiagnostics at every stage
ACCESSIBLE NEURODIAGNOSTICS AT EVERY STAGE PATHWAY EXAMPLE STROKE only For personal usePATIENT Stroke Emergency Triage and Post-Acute Care Hospital Arrival Acute Treatment Symptoms Response Imaging and Discharge Time since LSW 0 to 2.5 hours < 2.5 hours < 4 hours < 4 hours < 24 hours > 3 weeks to li
Slide 8: Market Opportunity
MARKET OPPORTUNITY Attractive Revenue Models Total Addressable Market Traditional CapEx or innovative OpEx selling model For personal use only ADDRESSABLE MARKET ~$15B offerings to provide buyer flexibility through direct or distributor sales channels. US GER, FRA, UK AUS ROW Capital equipment and M
Slide 9: EMView Pre-Validation Clinical Trial Results
EMView PRE-VALIDATION CLINICAL TRIAL RESULTS The EMView multi-site study involved 307 participants, including 277 acute suspected stroke patients, enrolled at Liverpool Hospital, Royal Melbourne Hospital, and Princess Alexandra Hospital. Reading learning curves ‘Haemorrhage (bleed) or not’ For perso
Slide 10: EMView Pre-Validation Clinical Trial Results: Exemplar case studies
EMView PRE-VALIDATION CLINICAL TRIAL RESULTS Exemplar case studies For personal use only Case #1 Case #3 R L R L Right convexity subarachnoid hemorrhage Left M2 occlusion ischaemic lesion on follow-up (1.7 mL) successfully detected and classified as MRI DWI (0.10 mL) successfully detected and haemor
Slide 11: Technology Overview
TECHNOLOGY OVERVIEW Algorithm portfolio Probabilistic anatomical imaging case studies EMVision Reconstruction Ground truth Base Advanced For personal use only Signals obtained in a matter of minutes Detection and classification What is it? CORE DIAGNOSTIC FEATURE Where is it? Localization of abnorma
Slide 12: Our Path to Market Entry
and First Responder OUR PATH TO MARKET ENTRY First commercial product We are here For personal use only Pre-Validation Trial Validation Trial (Pivotal) Regulatory Submission + Market Entry COMPLETED CY Q3 2024 TARGET COMMENCEMENT CY Q1 2025 2025+ ONWARDS Liverpool Hospital, Royal Melbourne Hospital,
Slide 13: First Responder Domestic Feasibility Study Overview
First Responder DOMESTIC FEASIBILITY STUDY OVERVIEW Targeted commencement CY Q1 2025 Study design Prospective, Convenience Sample, Usability, Pilot Study For personal use only Investigational sites Road Ambulance Service Air Ambulance Service (Royal Flying Doctor Service) Estimated duration < 6 mont
Slide 14: Partners & Collaborators
PARTNERS & COLLABORATORS Track record of securing and ongoing access to non-dilutive funding provides good flexibility Grant schemes are competitive and subject to due diligence before award For personal use only Clinical Research Partnership Commonwealth CRC-P Grant Program Collaborators Access to
Slide 15: Investment Highlights
INVESTMENT HIGHLIGHTS ✓ We have assembled a team of MedTech experts that have successfully done this before and created significant shareholder KEY 2025 CATALYSTS value For personal use only ✓ We have compelling support from the leading minds in First Responder neurological care Validation Pre-hospi
Slide 16: Capital Structure
CAPITAL STRUCTURE ASX TICKER: EMV Strong Capital Management Track Record Headquarters For personal use only 4.01, 65 Epping Road, • Secured ~$20m in non-dilutive grant funding since inception Macquarie Park Sydney, Australia • Cash position of $16.8m (30th Sept) • Modest historical cash burn Share P
Slide 17: Clinical Feedback
CLINICAL FEEDBACK “This is an exciting development in stroke and neurological care. We have found the EMVision scanner to be a very user-friendly portable imaging modality. The EMVision scanner has potential for wide application in both the prehospital and For personal use only acute hospital settin
EMVision Medical Devices — Ord Minnett Biotech and Medtech Conference 2024 on 6ix